AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune’s cor
Research Analysts’ updated eps estimates for Monday, August 7th: Achilles Therapeutics (NASDAQ:ACHL) had its buy rating reaffirmed by analysts at Chardan Capital. The firm currently has a $11.00 price target on the stock. AC Immune (NASDAQ:ACIU) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $16.00 price target on the […]
Equities Research Analysts’ updated eps estimates for Monday, April 17th: AC Immune (NASDAQ:ACIU) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Anheuser-Busch InBev SA/NV (NYSE:BUD) was downgraded by analysts at StockNews.com from a strong-buy rating to a buy rating. CrossAmerica Partners (NYSE:CAPL) was downgraded by analysts at StockNews.com from […]
Equities Research Analysts’ upgrades for Saturday, March 25th: AC Immune (NASDAQ:ACIU) was upgraded by analysts at StockNews.com from a sell rating to a hold rating. Alarm.com (NASDAQ:ALRM) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. Compañía de Minas Buenaventura S.A.A. (NYSE:BVN) was upgraded by analysts at StockNews.com from a […]